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Secondary malignancies in chronic myeloid leukemia patients
after imatinib-based treatment: long-term observation in CML
Study IV
MB Miranda1,20, M Lauseker2,20, M-P Kraus1, U Proetel1, B Hanfstein1, A Fabarius1, GM Baerlocher3, D Heim4, DK Hossfeld5, H-J Kolb6,
SW Krause7, C Nerl8, TH Brümmendorf9, W Verbeek10, AA Fauser11, O Prümmer12, K Neben13, U Hess14, R Mahlberg15, C Plöger16,
M Flasshove17, B Rendenbach18, W-K Hofmann1, MC Müller1, M Pﬁrrmann2, A Hochhaus19, J Hasford2, R Hehlmann1 and S Saußele1
Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs).
Long-term survival with imatinib is excellent with a 8-year survival rate of ∼ 88%. Long-term toxicity of TKI treatment, especially
carcinogenicity, has become a concern. We analyzed data of the CML study IV for the development of secondary malignancies. In
total, 67 secondary malignancies were found in 64 of 1525 CML patients in chronic phase treated with TKI (n= 61) and interferon-α
only (n= 3). The most common malignancies (n⩾ 4) were prostate, colorectal and lung cancer, non-Hodgkin’s lymphoma (NHL),
malignant melanoma, non-melanoma skin tumors and breast cancer. The standardized incidence ratio (SIR) for all malignancies
excluding non-melanoma skin tumors was 0.88 (95% conﬁdence interval (0.63–1.20)) for men and 1.06 (95% CI 0.69–1.55) for
women. SIRs were between 0.49 (95% CI 0.13–1.34) for colorectal cancer in men and 4.29 (95% CI 1.09–11.66) for NHL in women.
The SIR for NHL was signiﬁcantly increased for men and women. An increase in the incidence of secondary malignancies could not
be ascertained. The increased SIR for NHL has to be considered and long-term follow-up of CML patients is warranted, as the rate of
secondary malignancies may increase over time.
Leukemia advanced online publication, 26 February 2016; doi:10.1038/leu.2016.20
INTRODUCTION
Treatment of chronic myeloid leukemia (CML) has been
profoundly improved by the introduction of tyrosine kinase
inhibitors (TKIs). Long-term survival with imatinib is excellent with
a 5-and 8-year survival rate of 90% and 88%, respectively.1,2 The
life expectancy of patients who achieve complete cytogenetic
remission is not different from that of the general population,3,4
and is inﬂuenced mostly by comorbidities.5
The increased life expectancy requires closer long-term
observation of potential side effects. The development of
secondary malignancies is regarded as a common risk of
antineoplastic therapies. An increased rate of secondary malig-
nancies compared with the general population has been reported
in patients with Hodgkin’s lymphoma,6,7 chronic lymphocytic
leukemia8,9 and other lymphoproliferative diseases,10 as well as in
polycythemia vera11 and essential thrombocythemia.12,13
An increased rate of secondary malignancies has also been
described in patients who had received allogeneic stem cell
transplantation14–18 for various hematologic diseases. Exposure to
radiotherapy,19,20 chemotherapy and immunosuppression, either
disease or treatment related,21 have been suggested as risk factors
for secondary malignancies.
TKIs have also been discussed as risk factors for malignancies.
Preclinical data demonstrated an interaction of imatinib with DNA
repair mechanisms.22 In studies with rats, neoplastic changes
occurred in kidneys, urinary bladder, urethra, preputial and clitoral
glands, small intestine, parathyroid glands, adrenal glands and
non-glandular stomach.23
Another TKI effect that may be relevant for the development of
malignancies is the inhibition of T-lymphocytes and dendritic cells.
It has been shown that imatinib inhibits the effector function of
T-lymphocytes and impairs the differentiation of peripheral blood
progenitor cells into dendritic cells.24
These effects may facilitate the development of lymphatic
malignancies during long-term exposure to imatinib.
In CML, data on the incidence of secondary malignancies are
contradictory (see Supplementary Table 1). An increased rate of
prostate cancer was found in a French cohort of 189 CML patients
treated with imatinib.25 However, data from the Novartis registries
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of more than 9500 patients did not conﬁrm this observation, but
they were not obtained from randomized trials.26
Analyses of patient cohorts from multiple phase I and II trials at
the MD Anderson Cancer Center, who were treated with TKI for
CML and other myeloproliferative neoplasms, showed a risk of
secondary malignancies that was lower than expected in the
general population.27 In line with this is the analysis from Poland
of 221 CML patients under imatinib treatment (median of
61 months) with no increase of secondary malignancies.28
In contrast, two other studies demonstrated an higher incidence
in CML patients: (1) an analysis of the US-American SEER database
found a signiﬁcantly higher observed/expected ratio of secondary
malignancies in the imatinib era of 1.48 versus 1.06 in the pre-
imatinib era;29 (2) a study that crosslinked the Swedish CML
register to the Swedish Cancer registry found a standardized
incidence ratio (SIR) of 1.52 for a patient cohort from the imatinib
era;30 and (3) in a cohort of 1038 Czech and Slovakian CML
patients treated with TKI, the age-adjusted incidence rate of
secondary malignancies was found to be 1.5-fold higher than that
of the general population, but the difference was not statistically
signiﬁcant.31
However, CML itself has been discussed as a risk factor for solid
cancers and hematologic malignancies. The acquired translocation
t(9;22) at diagnosis of CML and additional chromosomal changes/
mutations as a sign of clonal evolution during the course of
disease show the potential of genetic instability in CML. Therefore,
progenitors may already have the capacity to enforce themselves
as distinct cells with enhanced malignancy resulting in solid
cancers/hematologic malignancies before or later than CML.32
Two epidemiological studies that analyzed cancer registries for
patients with CML in Sweden31,33 and patients with myeloproli-
ferative neoplasms including CML in Denmark34 showed an
increased risk of secondary malignancies in CML patients.
To further elucidate the risk for the development of secondary
malignancies in chronic-phase CML patients under treatment, we
analyzed data from the CML Study IV after a median treatment
duration of 45 years.
PATIENTS AND METHODS
Patients
CML study IV is a randomized 5-arm trial that compares imatinib 400 mg vs
imatinib 800 mg vs imatinib 400 mg in combination with interferon-α vs
imatinib 400 mg in combination with low-dose cytarabine and vs imatinib
400 mg after interferon failure.
The study was conducted as previously published.1
Inclusion criteria allowed the history of primary cancer if the disease was
in stable remission without impact on study procedures. A total of 102
malignancies were reported in 92 patients before the diagnosis of CML. If
relapses occurred within 5 years after diagnosis of primary cancer, they
were not considered for further analysis.
Median follow-up for all patients after diagnosis of CML was 67.5 months
(range, 0.12–124 months). Analysis was done according to intention-to-
treat principle, that is, for patients on primary imatinib and after switch of
therapy based on failure or intolerance.
Statistical analysis
SIRs35 were calculated from the age-speciﬁc rates from the German
reference population, obtained from the Robert Koch Institute.36 Patients
o15 years of age were excluded from the study and the groups 15–19
years and 485 years of age were not considered as 430 patient years
were observed. As usual, non-melanoma skin cancer was not considered.36
The 95% conﬁdence intervals (CIs) were calculated with ‘Mid-P exact test’
using the modiﬁcation of Miettinen37 as previously described.38 Overall
survival and progression-free survival as deﬁned by the ELN (European
LeukemiaNet) criteria39 were calculated using the Kaplan–Meier method.40
Cumulative incidences of second malignancies were estimated under the
presence of the competing risk of death.41 Unless otherwise speciﬁed, date
of diagnosis was considered as starting point for all time-to-event analyses.
If one type of malignancy occurred more than once in a patient it was
counted as one case according to the IACR (International Association of
Cancer Registries).42
If not speciﬁed otherwise, all computations were done with SAS 9.2 (SAS
Institute, Cary, NC, USA) or R 3.0.1.43
Ethics
The protocol followed the Declaration of Helsinki and was approved by the
ethics committee of the ‘Medizinische Fakultät Mannheim der Universität
Heidelberg’ and by local ethics committees of participating centers.
Written informed consent was obtained from all patients before they
entered the study.
RESULTS
Patient characteristics
From February 2002 to March 2012, 1551 CML patients in chronic
phase were randomized; 1525 were evaluable. Patient character-
istics are described in Table 1 and Figure 1.
Table 1. Patient characteristics of available patients and patients with secondary malignancies
Characteristic Patients who developed secondary
malignancies (n= 64)
Total cohort (n= 1525)
Age at diagnosis of CML, years 65 (30–88) 52 (16–88)
Age at diagnosis of secondary malignancy, years 66 (31–88) —
Time to secondary malignancy, years 2.4 (0.1–8.3) —
Follow-up after diagnosis of secondary malignancy, months 46.8 (0–104.6) —
Median overall survival, months Not reached Not reached
Patients with history of cancer, n 12 92
Malignancy was metastases or recurrence of primary malignancy, n 5 —
Time from primary cancer to secondary malignancy, years Range 5–19 —
Treatment for CML n (%) n (%)
Imatinib 400 mg 22 (34) 396 (26)
Imatinib+IFN 19 (30) 426 (28)
Imatinib 800 mg 9 (14) 417 (27)
Imatinib+AraC 4 (6) 158 (10)
IFN-standard 10 (16) 128 (8)
Of this, IFN only 3 15
Abbreviations: AraC, Cytarabin; CML, chronic myeloid leukemia; CP, chronic phase; IFN, interferon.
Secondary malignancies in CML
MB Miranda et al
2
Leukemia (2016) 1 – 8 © 2016 Macmillan Publishers Limited
Secondary malignancies
In total, 67 secondary malignancies in 64 (4.2%) patients were
found after a median follow-up of 67.5 months. Of these patients,
26 were female (41%). The median age of these 64 patients at
diagnosis of CML was 65 years (range, 30–88 years), and the
median age at diagnosis of the ﬁrst secondary malignancy after
diagnosis of CML was 66 years (range, 31–88 years). The median
time from diagnosis of CML to secondary malignancy was 2.4
years (range, 0.1–8.3 years).
So far, cumulative incidences of secondary malignancies among
the ﬁve therapy arms are similar; the 5-year cumulative incidence
varied between 1.9 and 6.3% (see Figure 1).
Two patients with secondary malignancy had been switched to
second-generation TKIs (dasatinib: 1, nilotinib: 1) because of
imatinib failure 3 days and 3 years, respectively, before the
diagnosis of the secondary malignancies. In addition, one patient
received allogeneic stem cell transplantation (44 years before
diagnosis of secondary malignancy).
Twelve of the patients with primary cancer before CML
diagnosis developed malignancies under TKI treatment. Six of
these patients had metastases or recurrence of the ﬁrst
malignancy 5–19 years after diagnosis of the primary cancers
(two patients with breast cancer and one patient with cancer of
unknown origin, prostate rectal and renal cell cancer).
The types of malignancies were: prostate (n = 9, 13%), colorectal
(n= 6, 9%), lung (n = 6, 9%), non-Hodgkin’s lymphoma (NHL; n= 7,
10%), malignant melanoma (n = 5, 7%), skin tumors (basalioma
n= 4 and squamous cell carcinoma n= 1, 7%), breast (n= 5, 7%),
pancreas (n= 4, 6%), kidney (n= 4, 6%), chronic lymphocytic
leukemia (n= 3, 4%), head and neck (n = 2, 3%), biliary (n = 2, 3%),
sarcoma (n = 2, 3%), and esophagus, stomach, liver, vulva, uterus,
brain and cancer of unknown origin (each n= 1, 1%, see Table 2).
Three patients had more than one malignancy while
receiving TKI. One patient developed a leiomyosarcoma and later
a liposarcoma, one patient had a NHL that recurred (recurrence
after 7 years) and one patient had prostate cancer and
developed a NHL.
Outcome of patients with secondary malignancies
Of the 64 patients, 8 were in complete cytogenetic remission,
31 in major molecular remission at the time of diagnosis of the
secondary malignancy. Two had progression of CML before
diagnosis of the secondary malignancy, and one of these
regained a remission before diagnosis of secondary malignancy
(Table 2).
After diagnosis of secondary malignancies, CML treatment
was continued without modiﬁcation in 36 patients (56%).
After a median follow-up time of 46.8 months (range
0–105 months) from time of diagnosis of the secondary
malignancy, 26 patients had died. Of these patients, 22 died
from the secondary malignancy, 2 from other causes (cerebellar
infarction, infection) and 2 from unknown causes. Progression of
CML was not a cause of death in any case. With a 4-year-survival
of 57% (95% CI 43–70%, median overall survival 6.5 years), the
overall survival and progression-free survival was signiﬁcantly
reduced in patients who developed secondary malignancies
(Figures 2a and b).
Statistical analysis
Cumulative incidences. Cumulative incidence of secondary malig-
nancies in patients450 years of age was signiﬁcantly higher than
in patients ⩽ 50 years old (Po0.001): at 6 years the cumulative
incidence was 8.1% (95% CI 9.2–10.5%) and 0.8% (95% CI 0.3–
1.9%), respectively (Figure 3).
No signiﬁcant differences were found between males and
females (cumulative incidence 4.6% (95% CI 3.2–6.5%) vs 5.2%
(95% CI 3.4–7.5%)) and EUTOS (European Treatment and Outcome
Study)44 high- vs low-risk patients at 6 years.
SIRs for secondary malignancies (without non-melanoma skin
tumors) in the CML population in comparison with the general
German population were 0.88 (95% CI 0.63–1.20) in men and 1.06
(95% CI 0.69–1.55) in women (38 and 24 patients observed vs 43.0
and 22.7 patients expected in the matched German population,
Figures 4a and b).
Patients with secondary malignancies, n = 64
Randomly assigned (final)
(n = 1,551)
Imatinib 400 mg
(n = 22)
Imatinib after IFN
(n = 10)
Imatinib +IFN
(n = 19)
Imatinib 800 mg
(n = 9)
Imatinib + AraC
(n = 4)
Imatinib 400 mg
(n = 396)
Imatinib after IFN
(n = 128)
Imatinib + IFN
(n = 426)
Imatinib 800 mg
(n = 417)
Imatinib + AraC
(n = 158)
Exclusions: 
no CML, not in CP, no consent (n = 13)
In study
(n = 1,538)
Withdrawal of consent (n = 3)
Evaluable for analysis 
(n = 1,525)
Baseline documentation /
date of diagnosis missing (n = 10)
Abbreviations: IFN, interferon; CP, chronic phase; n, number; AraC, Cytarabin 
Figure 1. Consort statement of the CML study IV and occurrence of secondary malignancies per recruitment arm.
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Cancer subtypes. Regarding the subtypes of secondary malig-
nancies, the numbers for prostate cancer, colorectal cancer, breast
cancer, malignant melanoma, pancreas and kidney cancer in CML
patients were not statistically signiﬁcantly different from expected
numbers of the general population. The SIRs were between 0.49
(colorectal in male) and 3.33 (kidney cancer in female) (Figure 4).
The number of cases of NHL however was signiﬁcantly higher in
the CML IV cohort than the expected number in the matched
German population. The SIR for male was 3.33 (95% CI 1.06–8.04)
and 4.29 for female (95% CI 1.09–11.66) (see Table 3 and
Figure 4b).
DISCUSSION
Overall, our data do not support an increased risk for secondary
malignancies in CML patients treated with imatinib as the SIR of
men and women were similar to that of general population.
However, looking at subtypes of malignancies we found a
signiﬁcant increase of the SIR for NHL for both sexes.
These data are in contrast to analyses of population-based
registries in Denmark34 and Sweden33 that found an increased risk
for secondary malignancies in CML patients. The observation
timeframes for both studies were between 1970 and 2007 and
between 1977 and 2008, respectively, and therefore mostly from
Figure 2. Probability of survival with or without the appearance of
secondary malignancies. (a) Overall survival from time of diagnosis
of CML. (b) Progression-free survival from time of diagnosis of
secondary malignancy.
Figure 3. Cumulative incidence of all secondary malignancies
according to age ⩽ 50 vs 450 years.
Figure 4. SIRs of secondary malignancies within CML study IV for
men and women compared with normal population for different
tumor types. (a): SIRs of men (b) and SIRs of women.
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the pre-TKI era. Both studies did not report on the speciﬁc
treatment, but one can conclude that most commonly hydro-
xyurea and interferon-α were given to the patients during
most of the time period. Knowing that BCR-ABL itself is a mutant
driver of malignancy, this could explain the discrepancy of the
studies.
The data from the SEER database contrast the above observa-
tions as in their study secondary malignancies in the pre-imatinib
era were less common than in the imatinib era.29
A recent analysis of 868 CML patients from the Swedish CML
registry diagnosed between 2002 and 2011 that were crosslinked
to the Swedish Cancer registry showed a 50% overall increased
risk of second malignancies compared with the normal
population.30 This is in line with the study by Rebora et al.33
A possible explanation of the differences to our analyses is that we
have a very well-described patient population with very good
remission rates under imatinib-based treatments.45 Therefore, the
BCR-ABL effect as described above may play a less important role
in the CML IV trial cohort and may contribute to lower incidence
rates of secondary malignancies.
In line with our observation is the study by Voglova et al.31 The
age-adjusted incidence rate of secondary malignancies in their
cohort of 1038 Czech and Slovakian CML patients treated with TKI
was 1.5-fold higher than the normal population, but the difference
was not statistically signiﬁcant.31
Subtypes
There are several studies showing an increasing risk for subtypes
of different cancers under TKI treatment. Verma et al.27 reported
on secondary malignancies in patients with different myelopro-
liferative neoplasms including CML. They found a smaller number
of secondary neoplasms than expected but an increased risk of
melanoma, kidney and endocrine cancers.
In our study the increased rate of prostate cancer, the most
common malignancy we found, was not statistically signiﬁcant.
This corresponds to data from the Novartis registries of clinical
trials and adverse event reports of more than 9500 patients and
more than 1 20 000 patient years and is in contrast to Roy et al.25
The increased frequency of NHL in our study was statistically
signiﬁcant. It must be considered that two of the seven cases
occurred in patients who had already developed a secondary
malignancy: in one case the documented NHL was a recurrence
after 7 years, and the other case was a NHL in a patient with a
previously documented prostate cancer. Another reason for the
increased number of NHL cases may be that three of the seven
cases were low-grade lymphomas that are easily missed in the
general population but found in a monitored study cohort. We
could not demonstrate a sex difference in appearance of NHL as
this was shown by Radivoyevitch et al.46
Prevalence
In addition, a high number of patients (92 out of 1525, 6.0%) with
malignancies that were diagnosed before the CML diagnosis were
randomized to our study. In an analysis of the SEER database,
Brenner et al.47 found that 14% of patients with CML had a
malignancy before CML was diagnosed. Usually, in ofﬁcial
publications like from the German Robert Koch Institute, cancer
prevalence is reported as a period prevalence, for example, 5-year
prevalence instead of point prevalence. Thus, no number for
comparison exists directly. However, the cancer prevalence in our
patient population seems to be high and a potential inﬂuence on
the pathogenesis of CML can be discussed.
The diagnosis of secondary malignancies had a signiﬁcantly
unfavorable impact on overall survival and progression-free
survival compared with other study patients of our trial.
Remarkably, the cause of death in all these patients was not
related to CML as no progression was observed.
Observation data from other disease entities, for example,
Hodgkin’s lymphoma, indicate a long latency time between time
after start of exposure to a risk factor and risk of secondary
malignancies. The relative risk increased from 2.2 after 5 years to
10.9 after 20 years.7 Peaks for the rate of secondary malignancies
were 5 to 9 years after chemotherapy and remained raised for
⩾ 25 years.6 Therefore, longer follow-up of CML patients is
warranted. In summary, there is no consistent distribution of
malignancies in the different reports.25–27,31,33,34 The risk of
secondary malignancies is increased in population-based studies
of CML patients,27,34 but not increased in case–control studies of
CML patients who are treated with TKI.27,28,31 So far, it is
impossible to dissect patient selection in the observed patient
populations from the impact of CML treatment on the risk of
secondary malignancies.
Therefore, it is speculative if secondary malignancies occur after
long exposure to TKI. Ideally, long-term follow-up on large cohorts
of CML patients under treatment is warranted. As analyses of
cancer registries often do not integrate complete data on
treatment, a solution could be a registry on CML trial patients
after end of study.
Table 3. Standardized incidence rates of secondary malignancies (excluding non-melanoma skin cancer)
Male Female
CML IV Matched German
population
Observed/expected (95%
conﬁdence interval)
CML
IV
Matched German
population
Observed/ expected (95%
conﬁdence interval)
Overall, n 38 43.0 0.88 (0.63–1.20) 24 22.7 1.06 (0.69–1.55)
Age 450 years, n 37 40.6 0.91 (0.65–1.24) 20 20.5 1.02 (0.65–1.54)
Age o50 years, n 1 2.4 0.42 (0.02–2.06) 4 2.2 1.82 (0.58–4.39)
Secondary malignancy type (types with only one occurence were not shown)
Prostate, n 9 11.8 0.76 (0.37–1.40)
Colorectal, n 3 6.1 0.49 (0.13–1.34) 3 2.8 1.07 (0.27–2.92)
Lung, n 4 6.1 0.66 (0.21–1.58) 2 1.7 1.18 (0.20–3.89)
NHL, n 4 1.2 3.33 (1.06–8.04) 3 0.7 4.29 (1.09–11.66)
Breast, n 5 7.8 0.64 (0.23–1.42)
Pancreas, n 2 1.3 1.54 (0.26–5.08) 2 0.7 2.86 (0.48–9.44)
Kidney, n 2 1.6 1.25 (0.21–4.13) 2 0.6 3.33 (0.56–11.01)
Abbreviations: CML, chronic myeloid leukemia; NHL, non-Hodgkin’s lymphoma.
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